{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:46:23Z","timestamp":1791888383686,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2322-2","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["A review of the European LeukemiaNet recommendations for the management of CML"],"prefix":"10.1007","volume":"94","author":[{"given":"Michele","family":"Baccarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2322_CR1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, on behalf of the European LeukemiaNet (2007) Chronic myeloid leukemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"2322_CR2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to. 2008. J Clin Oncol 29:2514\u20132520","journal-title":"J Clin Oncol"},{"issue":"9","key":"2322_CR3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981\u20131987","journal-title":"Blood"},{"key":"2322_CR4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"2322_CR5","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"issue":"6","key":"2322_CR6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"key":"2322_CR7","unstructured":"O\u2019Brien S, Abboud CN, Akhtari M et al (2014) Clinical practice guidelines in oncology. Chronic Myelogenous Leukemia, Version 3, National Comprehensive Cancer Network (NCCN). http:\/\/www.nccn.org"},{"key":"2322_CR8","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade De","year":"2008","unstructured":"De Lavallade H, Apperley JF, Khorashad J et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analsys. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"2322_CR9","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"T Hughes","year":"2008","unstructured":"Hughes T, Branford S, White DL et al (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600\u00a0mg\/day of imatinib as initial therapy. Blood 112:3965\u20133972","journal-title":"Blood"},{"key":"2322_CR10","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F et al (2009) A comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the first-line treatment of high risk, Philadelphia-positive, chronic myeloid leukemia. A European LeukemiaNet Study. Blood 113:4497\u20134504","journal-title":"Blood"},{"key":"2322_CR11","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","volume":"27","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Kantarjian HM, Goldberg SL et al (2009) High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754\u20134759","journal-title":"J Clin Oncol"},{"issue":"8","key":"2322_CR12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, Lopez-Garrido P, Montero MI et al (2010) Early intervention during imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 95(8):1317\u20131324","journal-title":"Haematologica"},{"key":"2322_CR13","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521","journal-title":"N Engl J Med"},{"issue":"21","key":"2322_CR14","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 117(21):5591\u20135599","journal-title":"Blood"},{"key":"2322_CR15","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634\u20131642","journal-title":"J Clin Oncol"},{"issue":"12","key":"2322_CR16","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B et al (2011) Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118(12):3228\u20133235","journal-title":"Blood"},{"issue":"19","key":"2322_CR17","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100\u00a0mg versus imatinib 400\u00a0mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120(19):3898\u20133905","journal-title":"Blood"},{"key":"2322_CR18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular response to imatinib or interferon alpa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1421\u20131432","journal-title":"N Engl J Med"},{"key":"2322_CR19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SO et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"2322_CR20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"2322_CR21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Baccarani M, Guilhot F et al (2009) Phase III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424\u2013434","journal-title":"J Clin Oncol"},{"issue":"24","key":"2322_CR22","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259","journal-title":"N Engl J Med"},{"issue":"24","key":"2322_CR23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260\u20132270","journal-title":"N Engl J Med"},{"key":"2322_CR24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadlephia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851","journal-title":"Lancet Oncol"},{"issue":"10","key":"2322_CR25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26(10):2197\u20132203","journal-title":"Leukemia"},{"issue":"28","key":"2322_CR26","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30(28):3486\u20133492","journal-title":"J Clin Oncol"},{"key":"2322_CR27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123","journal-title":"Blood"},{"key":"2322_CR28","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Melo JV, Baccarani M and Thiele J (2008) Chronic myelogenous leukemia BCR-ABL1 positive in, Swerdlow SH, Campo E, Harris NL et al (eds), WHO classification of Tumors of Hematopoietic and Lymphoid Tissues, IARC, Lion 2, pp 32-37","DOI":"10.1309\/AJCPUN89CXERVOVH"},{"issue":"4","key":"2322_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120(4):737\u2013747","journal-title":"Blood"},{"key":"2322_CR30","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118:6760\u20136768","journal-title":"Blood"},{"issue":"4","key":"2322_CR31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G et al (2012) Additional chromosome abnormalities in Philadelphia-positive clone: adverse prognostic influene on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 120(4):761\u2013767","journal-title":"Blood"},{"key":"2322_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"2322_CR33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2322_CR34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692","journal-title":"Blood"},{"key":"2322_CR35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201336","journal-title":"Blood"},{"issue":"11","key":"2322_CR36","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cross NC, Erben P et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23(11):1957\u2013196 5","journal-title":"Leukemia"},{"issue":"10","key":"2322_CR37","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172\u20132175","journal-title":"Leukemia"},{"key":"2322_CR38","doi-asserted-by":"crossref","unstructured":"Branford S, Yeung DT, Parker WT, et al (2014) Prognosis for patients with CML and >10\u00a0% BCR-ABL1 after 3\u00a0months of imatinib depends on the rate of BC R-ABL1 decline. Blood., in press","DOI":"10.1182\/blood-2014-03-566323"},{"key":"2322_CR39","doi-asserted-by":"crossref","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, et al (2014) Velocity of early BCR-ABL transcript elimination as an optimal predictor of outcome in chronic myeloid leukemia patients in chronic phase on treatment with imatinib. Leukemia., in press","DOI":"10.1038\/leu.2014.153"},{"issue":"5","key":"2322_CR40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutations analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208\u20131215","journal-title":"Blood"},{"issue":"10","key":"2322_CR41","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","volume":"119","author":"WT Parker","year":"2012","unstructured":"Parker WT, Ho M, Scott HS et al (2012) Poor response to second-line tyrosine kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resisstance profile. Blood 119(10):2234\u2013223","journal-title":"Blood"},{"issue":"9","key":"2322_CR42","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K et al (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 122(9):1634\u20131648","journal-title":"Blood"},{"key":"2322_CR43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P et al (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor resistant CML: frequency and clonal relationship. Blood 121:489\u2013498","journal-title":"Blood"},{"key":"2322_CR44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"NP Shah","year":"2010","unstructured":"Shah NP, Kim DW, Kantarjian H et al (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100\u00a0mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232\u2013240","journal-title":"Haematologica"},{"issue":"4","key":"2322_CR45","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141\u20131145","journal-title":"Blood"},{"key":"2322_CR46","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TK et al (2011) Safety and efficacy of bosutinib (SKY-606) in chronic phase Philadelphia-chromosome positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118:4567\u20134576","journal-title":"Blood"},{"key":"2322_CR47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibartz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107\u2013112","journal-title":"Leukemia"},{"issue":"3","key":"2322_CR48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C et al (2012) Assessment of BCR-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232\u2013238","journal-title":"J Clin Oncol"},{"key":"2322_CR49","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"issue":"2","key":"2322_CR50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE et al (2012) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120(2):291\u2013294","journal-title":"Blood"},{"issue":"24","key":"2322_CR51","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A et al (2013) Eraly responses predict better outcomes in patients with newly diagnoses chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121(24):4867\u20134874","journal-title":"Blood"},{"issue":"9","key":"2322_CR52","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123(9):1353\u20131360","journal-title":"Blood"},{"issue":"4","key":"2322_CR53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantrajian HM, Saglio G et al (2014) Early response with dasatinid or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494\u2013500","journal-title":"Blood"},{"key":"2322_CR54","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP et al (2012) Ponatinib in refractory chromosome-positive leukemias. N Engl J Med 367:2075\u20132088","journal-title":"N Engl J Med"},{"key":"2322_CR55","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia. New Engl J Med 369:1783\u20131796","journal-title":"New Engl J Med"},{"key":"2322_CR56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26:214\u2013224","journal-title":"Leukemia"},{"key":"2322_CR57","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimation of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127","journal-title":"Cancer"},{"issue":"1","key":"2322_CR58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","volume":"98","author":"R Gurion","year":"2013","unstructured":"Gurion R, Gafter-Gvili A, Vidal L et al (2013) Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 98(1):95\u2013102","journal-title":"Haematologica"},{"key":"2322_CR59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood 109:58\u201360","journal-title":"Blood"},{"issue":"10","key":"2322_CR60","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24(10):1719\u20131724","journal-title":"Leukemia"},{"key":"2322_CR61","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2322-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2322-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:23:54Z","timestamp":1598851434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":61,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2322"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2322-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}